Edition:
United States

Stemline Therapeutics Inc (STML.O)

STML.O on Consolidated Issue listed on NASDAQ Capital Market

11.00USD
22 Sep 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$11.00
Open
$11.00
Day's High
$11.20
Day's Low
$10.82
Volume
240,738
Avg. Vol
199,746
52-wk High
$14.60
52-wk Low
$5.50

Chart for

About

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the... (more)

Overall

Beta: -0.16
Market Cap(Mil.): $278.08
Shares Outstanding(Mil.): 25.28
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.89 16.34
EPS (TTM): -- -- --
ROI: -- 3.08 14.66
ROE: -- 4.82 14.00

BRIEF-Stemline Therapeutics files for mixed shelf offering of up to $175 mln

* Stemline Therapeutics Inc files for mixed shelf offering of up to $175 million - SEC filing‍​ Source text: (http://bit.ly/2wFKm1k) Further company coverage:

Aug 08 2017

BRIEF-Stemline Therapeutics Q2 loss per share $0.66

* Stemline Therapeutics reports second quarter 2017 financial results

Aug 08 2017

BRIEF-Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN

* Stemline Therapeutics presents SL-401 updated stage 1 and 2 data from ongoing pivotal trial in BPDCN and safety experience across multiple indications, today at EHA

Jun 23 2017

BRIEF-Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 BPDCN trial

* Stemline Therapeutics to present SL-401 updated data from stage 1 and 2 of ongoing pivotal phase 2 bpdcn trial at upcoming European Hematology Association (EHA) meeting Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Stemline Therapeutics Q1 loss per share $0.67

* Stemline therapeutics reports first quarter 2017 financial results

May 10 2017

BRIEF-Stemline Therapeutics reports completion of enrollment in stage 3 sl-401 pivotal trial in BPDCN

* Stemline Therapeutics announces completion of enrollment in stage 3 of the sl-401 pivotal trial in bpdcn

Mar 23 2017

Competitors

  Price Chg
Astellas Pharma Inc (4503.T) ¥1,419 -26.00
Eisai Co., Ltd (4523.T) ¥5,867 +46.00
Sumitomo Dainippon Pharma Co Ltd (4506.T) ¥1,477 -27.00
Pfizer Inc. (PFE.N) $35.96 -0.01
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Roche Holding Ltd. (ROG.S) CHF248.00 -1.00
Roche Holding Ltd. (RO.S) CHF248.00 -1.00
Sanofi SA (SASY.PA) €84.12 +0.25
GlaxoSmithKline plc (GSK.L) 1,474.00 +6.00

Earnings vs. Estimates